Wall Street Zen upgraded shares of Enovis (NYSE:ENOV – Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
ENOV has been the subject of a number of other reports. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research note on Wednesday, July 29th. Citizens Jmp dropped their price objective on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a report on Wednesday, September 2nd. Needham & Company LLC reduced their price target on Enovis from $52.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, October 12th. BMO Capital Markets set a $27.00 target price on shares of Enovis in a report on Tuesday, September 1st. Finally, Canaccord Genuity Group reduced their price objective on Enovis from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Monday, August 17th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $37.25.
View Our Latest Stock Analysis on Enovis
Enovis Stock Performance
NYSE:ENOV opened at $20.59 on Friday. The firm has a 50-day moving average of $19.91 and a two-hundred day moving average of $23.06. Enovis has a 1-year low of $16.70 and a 1-year high of $32.41. The stock has a market cap of $1.19 billion, a P/E ratio of 6.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00.
Enovis (NYSE:ENOV – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the prior year, the company earned $0.79 earnings per share. The firm’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis will post 3.15 earnings per share for the current fiscal year.
Insider Activity at Enovis
In related news, CEO Damien Mcdonald purchased 13,035 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $19.15 per share, with a total value of $249,620.25. Following the completion of the transaction, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This trade represents a 5.57% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Oliver Engert purchased 5,140 shares of Enovis stock in a transaction that occurred on Thursday, September 3rd. The shares were acquired at an average price of $19.46 per share, with a total value of $100,024.40. Following the acquisition, the insider directly owned 61,238 shares of the company’s stock, valued at $1,191,691.48. This trade represents a 9.16% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought a total of 23,293 shares of company stock valued at $449,599 over the last ninety days. Company insiders own 2.90% of the company’s stock.
Hedge Funds Weigh In On Enovis
Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc grew its holdings in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of Enovis during the 2nd quarter worth approximately $36,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Enovis during the 2nd quarter worth approximately $39,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis during the 2nd quarter worth approximately $48,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Enovis in the 3rd quarter worth approximately $55,000. 98.45% of the stock is currently owned by institutional investors.
Enovis Company Profile
Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.
The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.
Featured Articles
- Five stocks we like better than Enovis
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
